Lion's Mane
The Cognition Mushroom and What the Trials Actually Show
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Lion's mane has more human cognitive data than most "brain" supplements, but it remains preliminary. The most-cited trial (Mori 2009) gave adults aged 50-80 with mild cognitive impairment 3g/day for 16 weeks and found improving cognitive scores at weeks 8, 12, and 16, with the benefit fading 4 weeks after stopping, suggesting continued use is needed. A separate 49-week pilot in mild Alzheimer's disease using erinacine A-enriched mycelia (about 49 participants) reported improvements on the Mini-Mental State Examination and daily-living measures. Smaller studies suggest possible mood/anxiety benefits and acute effects on a cognitive (Stroop) task, while some trials in healthy young adults found no meaningful change. The honest summary: a plausible mechanism plus several small, mostly short, mostly East-Asian trials showing promise, especially in older adults with cognitive impairment, but not yet the large, replicated evidence that would justify the confident "brain-boosting" marketing.
Reference only. Not medical advice.
What can go wrong
Lion's mane is generally well tolerated in studies, with the most common complaints being mild digestive upset, and it is treated as safe when eaten as food. The clearest documented caution is allergy: there is a published case of anaphylaxis after eating it and an older case of severe lung inflammation (acute respiratory distress syndrome) linked to an extract, so anyone with a mushroom allergy should be careful. Possible effects on blood sugar and bleeding mean people who take diabetes or blood-thinning medication, or who are approaching surgery, should be cautious. Product quality varies widely, since mycelium-on-grain and fruiting-body extracts carry different active compounds and labeling is inconsistent. Evidence in pregnancy, breastfeeding, and children is essentially absent. Because it is being explored for cognition and mood, anyone considering it for memory concerns, low mood, or anxiety should talk with a qualified clinician rather than self-treating, so that a treatable condition is not missed.
Lion's mane (Hericium erinaceus) is a shaggy white mushroom eaten and used as a tonic for centuries in China and Japan, now the flagship of the nootropic supplement boom. Its case is unusual for a brain supplement in that the mechanism is genuinely plausible: compounds called hericenones and erinacines stimulate nerve growth factor in laboratory and animal studies. The human evidence is more than most rivals can show but remains preliminary. The most-cited trial (Mori 2009) found that older adults with mild cognitive impairment improved over 16 weeks at 3g a day, with the gains fading once they stopped taking it; a 49-week pilot in early Alzheimer's using an erinacine-enriched form showed improvement on memory and daily-function scores. Studies in healthy young adults have been largely negative. The honest read is a real mechanism and encouraging small trials in impaired older adults, well short of the large replicated evidence the confident marketing implies, with product form the main practical caveat.
The flagship nootropic mushroom, with a real NGF mechanism and several small, promising cognition trials, but not yet the big evidence its "brain-boost" marketing implies.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Lion's mane contains hericenones and erinacines, compounds that in laboratory and animal studies stimulate nerve growth factor (NGF) and show BDNF-like neurotrophic effects, supporting the growth, repair, and plasticity of neurons. This gives a genuinely plausible biological basis for cognitive effects, the question is how well the lab mechanism translates to humans, where the evidence is real but still thin.
What people get wrong
Often saidLion's mane is a proven brain-booster for everyone.
ActuallyThe NGF mechanism is real and trials in older adults with mild cognitive impairment are encouraging, but the human evidence is small, mostly short, and heterogeneous. A 2025 controlled trial in healthy young adults found no overall cognitive or mood benefit from a single dose. A 2025 systematic review of 9 human studies called the effects modest and limited by sample size and duration. It is promising, not proven, and the marketing runs ahead of the data.
Often saidAny lion's mane product delivers the same effect the trials found.
ActuallyProducts differ a great deal. The fruiting body carries hericenones; the mycelium carries erinacines, and the standout Alzheimer's pilot used a specific erinacine-A-enriched mycelium rather than a generic powder. Trials have used forms ranging from 0.5g of powder to erinacine-enriched extracts, so a random supplement may not match what was studied.
Often saidThe cognitive benefit builds and lasts.
ActuallyIn the Mori 2009 trial the improvement appeared during 16 weeks of daily intake and then declined after people stopped, according to the study and the Alzheimer's Drug Discovery Foundation's review. Whatever effect exists in that population looks dependent on continued use, not a durable rewiring.
Who profits, and who pushes back
Mori (2009) & MCI trials
Found improved cognitive scores in older adults with mild cognitive impairment over 16 weeks at 3g/day, with benefit fading after supplementation stopped.
Alzheimer's-pilot researchers
Reported improvements on cognitive and daily-living measures over 49 weeks in mild Alzheimer's using erinacine A-enriched mycelia, in a small pilot needing replication.
Healthy-adult trial reviewers
Note that some trials in healthy young adults found no meaningful cognitive change, so benefits may be clearest in impaired older populations.
Nootropic marketing
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sells lion's mane powders, capsules, and coffees on confident focus and brain-boost claims that outrun the small, preliminary human evidence, with a clear commercial interest.
Where the research comes from
Most of the published research on this comes from one place. 85% of it is from China (TCM). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| China (TCM) | 85% |
| Japan (yamabushitake) | 82% |
| Global nootropic market | 78% |
How we got here
Lion's mane grows across the temperate forests of East Asia, and Chinese and Japanese healers were the first to fold it into medicine. In China it is hou tou gu, monkey head mushroom, prized as a food and a tonic for the spleen, digestion, and general vitality in classical Chinese medicine. In Japan it is yamabushitake, named for the yamabushi, the ascetic mountain monks of Shugendo, who ate it during their practice; the association with monastic focus is part of why it carries a reputation for mental clarity. Cultivation was difficult for generations, keeping it scarce, until Chinese growers reported reliable artificial cultivation in the late 1980s. Scientific attention arrived when Hirokazu Kawagishi's group in Japan isolated the nerve-growth-factor-stimulating hericenones in 1991 and erinacines in 1994. The Mori mild-cognitive-impairment trial in 2009 became the reference human study, and through the 2010s and 2020s lion's mane grew into a worldwide nootropic product well ahead of its clinical evidence.
- Pre-modernEaten and used as a tonic in Chinese medicine (hou tou gu) and by Japan's yamabushi mountain monks (yamabushitake)
- 1988Chinese growers report reliable artificial cultivation, expanding supply
- 1991Kawagishi's group isolates hericenones C, D and E from the fruiting body as NGF-synthesis stimulators (Tetrahedron Letters)
- 1994Kawagishi's group isolates erinacines from the mycelium, stronger NGF stimulators than the hericenones
- 2009Mori double-blind placebo-controlled trial in mild cognitive impairment (n=30); benefit faded after intake stopped
- 2010Nagano trial in 30 women reports lower depression and anxiety scores after 4 weeks
- 2020Li 49-week pilot in early Alzheimer's using erinacine-A-enriched mycelia shows gains on MMSE and daily-living scores
- 2025Systematic review of 9 human studies calls cognition and mood evidence modest and limited; a healthy-young-adult trial finds no overall benefit
How it is understood
Lion's mane (Hericium erinaceus), known in Japan as yamabushitake and used in Chinese medicine, is a shaggy white mushroom long valued in East Asia as both food and tonic, traditionally associated with the stomach and spleen and, in TCM terms, with memory and emotional steadiness. It was eaten and taken as a tonic over time rather than as an acute remedy. In the past decade it has become one of the most popular nootropic ("smart") supplements in the world, sold as powders, capsules, and coffees on promises of focus, memory, and brain health, making it the flagship of the "functional mushroom" boom.
At a glance
- Plant
- Hericium erinaceus (yamabushitake)
- Active
- Hericenones, erinacines (NGF/BDNF)
- Key trial
- Mori 2009: MCI, 3g/day, 16 wks, benefit faded after stopping
- Status
- Promising but preliminary
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Lion's Mane. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Mori 2009: 16-week double-blind placebo-controlled trial in 30 older adults with mild cognitive impairment; scores improved on intake and declined after stopping
Mori 2009 cognitive gains declined after treatment stopped; overall human cognition evidence judged limited
Li 2020: 49-week pilot in early Alzheimer's (49 randomized, 41 completed) with erinacine-A-enriched mycelia; significant gains on MMSE and IADL
Nagano 2010: 30 women, 4 weeks of Hericium erinaceus cookies; lower depression (CES-D) and indefinite-complaint scores
2025 systematic review of 9 human studies (5 RCTs, 3 pilot trials, 1 cohort); cognition and mood benefits modest and limited by sample size, duration, heterogeneity; side effects and product variability noted
Single-dose trial in healthy young adults found no overall cognitive or mood benefit, only isolated task effects
Hericenones C, D and E from the fruiting body stimulate NGF synthesis; erinacines from the mycelium do so more strongly (mechanism origin, Kawagishi)
First reported case of anaphylaxis after eating lion's mane mushroom (hives, swelling, GI symptoms; positive skin test)
Watson & Kobernick, Dangers at the Dinner Table, Annals of Allergy, Asthma & Immunology
Case of acute respiratory distress syndrome linked to Hericium erinaceum extract use (allergic reaction)
Nakatsugawa et al., yamabushitake extract-induced ARDS, via PubMed
Traditional East Asian names and use: hou tou gu (monkey head) in China; yamabushitake, after Shugendo mountain monks, in Japan; artificial cultivation reported 1988